Denali Therapeutics Inc. (DNLI)
Chart Events
Performance Outlook
| Previous Close | 36.23 |
| Open | 35.87 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 35.60 - 36.30 |
| 52 Week Range | 20.24 - 56.80 |
| Volume | |
| Avg. Volume | 622,156 |
| Market Cap | 4.353B |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | 151.02 |
| EPS (TTM) | 0.24 |
| Earnings Date | May 02, 2022 - May 06, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.08 |
- Zacks
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
- Zacks
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights. “The Phase 1 study of DNL919 (ATV:TREM2) is now underway, making this our third BBB Transport Vehicle (TV)-enabled program,
